YMAB Live signals | Maximize Profits with Getagraph.com

BUY 93148 min ago

@ $15.77

Issued: 14 Feb 2024 @ 14:20

Return: -4.88%

Previous signal: Feb 13 - 15:31

Previous signal: Sell

Return: 6.45 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	398 334
Average Volume	387 509
Market Cap	656.66M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.120 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-30.61
ATR14	$0.0340 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Tagliaferri Mary	Buy	27 900	Stock Option (right to buy)
2024-03-12	Tagliaferri Mary	Buy	4 660	Common Stock
2024-02-29	Tagliaferri Mary	Buy	0
2024-03-05	Rajah Vignesh	Sell	1 711	Common Stock
2024-03-05	Gad Thomas	Sell	3 900	Common Stock

INSIDER POWER
77.72
Last 98 transactions
Buy: 3 651 211 \| Sell: 357 293

Volume Correlation

Long: 0.00 (neutral)

Short: 0.63 (weak)

Signal:(42.622) Neutral

Y-mAbs Therapeutics, Inc Correlation

10 Most Positive Correlations
MAGS	0.928
IMUX	0.912
SIEN	0.897
BWAY	0.89
APOP	0.886
MOSY	0.886
CMLF	0.865
IKNX	0.858
THMO	0.811

10 Most Negative Correlations
WLTW	-0.889
MXIM	-0.865
MCRI	-0.835
LMST	-0.814
PCVX	-0.808

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Y-mAbs Therapeutics, Inc Correlation - Currency/Commodity

0.18
( neutral )

0.55
( weak )

0.00
( neutral )

-0.28
( neutral )

-0.38
( neutral )

0.40
( neutral )

Y-mAbs Therapeutics, Inc Financials

Annual	2023
Revenue:	$84.82M
Gross Profit:	$73.40M (86.54 %)
EPS:	$-0.490

Q4	2023
Revenue:	$23.36M
Gross Profit:	$21.32M (91.27 %)
EPS:	$-0.0226

Q3	2023
Revenue:	$20.45M
Gross Profit:	$17.81M (87.07 %)
EPS:	$-0.180

Q2	2023
Revenue:	$20.75M
Gross Profit:	$16.10M (77.60 %)
EPS:	$-0.140

Financial Reports:

No articles found.

Y-mAbs Therapeutics, Inc

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.